摘要
本研究旨在检测淋巴瘤患者血浆中miR-21、miR-155、miR-210的表达,分析其与临床特征的相关性并探讨其在淋巴瘤诊断、评价疗效及预后方面的作用。运用RT-PCR方法检测淋巴瘤患者(55例)、淋巴结炎性肿大患者(10例)和正常对照(27名)血浆中miR-21、miR-155、miR-210的表达。结果表明,淋巴瘤患者血浆中miR-21、miR-155、miR-210的表达量均明显高于正常对照及淋巴结炎性肿大患者(P<0.05),淋巴结炎性肿大患者血浆中miR-21、miR-210的表达量与正常对照无显著差异。淋巴瘤患者血浆中miR-21的表达随血清乳酸脱氢酶水平增高而增高。初治淋巴瘤患者血浆中miR-21、miR-210的表达量明显高于6个疗程以上患者的表达量(P<0.05)。miR-21、miR-155、miR-210用于淋巴瘤的诊断准确度分别可达56.4%、65.3%、47.6%,三者联合诊断率可达82.7%。结论:淋巴瘤血浆中miR-21、miR-155、miR-210的表达量增高,检测三者在血浆中的表达量有助于临床淋巴瘤的诊断及疗效、预后的判断。
This study was purposed to investigate the expressions of miR-21,miR-155 and miR-210 in plasma of patients with lymphoma,and explore their role played in diagnosis,evaluation of chemotherapy effect and prognosis of lymphoma.The expressions of miR-21,miR-155 and miR-210 were assayed by RT-PCR in plasma of 54 cases of lymphoma,10 cases of lymphonode inflammation and 27 cases of normal controls.The results indicated that the expressions of miR-21,miR-155 and miR-210 in plasma of lymphoma patients were higher than those of control group and lymphonode inflammation group（P0.05）.The expressions of miR-21 and miR-210 in plasma of control group and lymphonode inflammation group had no significant differences（P 0.05）.The expression of miR-21 in plasma of lymphoma patient group significantly correlated with their serum LDH level.The expressions of miR-21 and miR-210 in plasma of previously untreated lymphoma patient group were higher than those of the patients treated for 6 or more courses（P0.05）.The diagnostic accuracy of miR-21,miR-155 and miR-210 used for lymphoma patients was 56%,65%,48% respectively,and reached to 83% when combined three of them.It is concluded that the expressions of miR-21,miR-155 and miR-210 in plasma of lymphoma patients were significantly higher.Detection of these 3 miRNA in plasma of patients can contribute to the clinical diagnosis,treatment and prognosis evaluation of lymphoma.
出处
《中国实验血液学杂志》
CAS
CSCD
北大核心
2012年第2期305-309,共5页
Journal of Experimental Hematology
基金
国家自然科学基金(编号81170472)
"十一五"国家科技支撑计划(编号2008BA161B00)
高等学校博士学科点专项科研基金(编号200800620004)
卫生行业科研专项项目(编号201002024)
天津市自然科学基金(编号09JCYBJC11200)
天津市科技支撑计划重点项目重大疾病防治专项基金(编号07ZCGYSF00600)
天津医科大学重点学科基金(编号2009xk51)
天津医科大学基金(编号2006KY31)
